Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Jardim Perassi, Bruna Victorasso ^a,b   Arbab, Ali S ^c   Ferreira, Lívia Carvalho ^a,b   Borin, Thaiz Ferraz ^b   Varma, Nadimpalli R S ^c   Iskander, A S M ^c   Shankar, Adarsh ^c   Ali, Meser M ^c   De Campos Zuccari, Debora Aparecida Pires ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; SOMATOMEDIN C; TECHNETIUM 99M; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DENSITOMETRY; DIGITAL CALIPER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; MELATONIN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 84897435006     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085311     Document Type: Article

References (66)

1. Instituto Nacional do Câncer (INCA) (2010) Estimativas da incidência e mortalidade por câncer no Brasil. Ministério da Saúde. Available: http://www.inca.gov.br/estimativa/2010/index.asp?link= conteudo-view.asp&ID = 5. Accessed 2013 Jul 23.
2. Bennett IC, Gattas M (2000) The management of familial breast. Breast 9: 247-263.
3. Instituto Nacional do Câncer (INCA) (2005) Incidência de Câncer no Brasil. Ministério da Saúde. Available: http://www.inca.gov.br/estimativa/2006/versaofinal.pdf. Accessed 2013 Jul 23.
4. Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA (1997) Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev 16: 5-27. (Pubitemid 27219469)
5. Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, et al. (2010) Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J. Pineal Res 48: 178-184.
6. Hilmi C, Guyot M, Pagès G (2012) VEGF spliced variants: possible role of antiangiogenesis therapy. J Nucleic Acids doi: 10.1155/2012/162692
7. Ambasta RK, Sharma A, Kumar P (2011) Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 3: 26.
8. Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17: 1359-1370.
9. Arbab AS (2012) Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma. Histol Histopathol 27: 549-557.
10. Semenza GL (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 8: 62-67.
11. Kallergi G, Markimanolaki H, Giannoukaraki V, Papadaki MA, Strati A, et al. (2009) Hypoxia-inducible HIF-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 11: 84.
12. Vordermark D (2010) Hypoxia-specific targets in cancer therapy: role of splice variants. BMC Med 8: 45.
13. Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS (2011) Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol 5: 193.
14. Stefanini MO, Wu FT, Gabhann FM, Popel AS (2008) A compartment model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2: 2-77.
15. Romon R, Adriaenssens E, Lagadec C, Germain E, Hondermarck H, et al. (2010) Nerve growth factor promotes breast cancer angiogenesis by activating multiple pathways. Mol Cancer 9: 157.
16. Greenberg S, Rugo HS (2010) Triple-negative breast cancer: role of antiangiogenic agents. Cancer J 16: 33-38.
17. Carpini JD, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13: 43-58.
18. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, et al. (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 12: 557-567.
19. Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, et al. (2008) Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J 22: 3234-3246.
20. Silverman MD, Haas CS, Rad AM, Arbab AS, Koch AE (2007) The role of vascular cell adhesion molecule 1/very late activation antigen 4 in endothelial progenitor cell recruitment to rheumatoid arthritis synovium. Arthritis Rheum 56: 1817-1826. (Pubitemid 47110381)
21. Janic B, Guo AM, Iskander AS, Varma NR, Scicli AG, et al. (2008) Human cord blood-derived AC133 + progenitor cells preserve endothelial progenitor characteristics after long term in vitro expansion. PLoS One 5: e9173.
22. Kerbel RS (2008) Tumor angiogenesis. N. Engl. J. Med 358: 2039-2049.
23. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7: 1152-1160.
24. Maganhin CC, Carbonel AA, Hatty JH, Fuchs LF, Oliveira-Júnior IS, et al. (2008) Melatonin eddects on the female genital system: a brief review. Rev Assoc Med Bras 54: 267-271.
25. Luchetti F, Canonico B, Betti M, Arcangeletti M, Pilolli F, et al. (2010) Melatonin signaling and cell protection function. FASEB J 24: 3603-3624.
26. Di Bella G, Mascia F, Gualano L, Di Bella L (2013) Melatonin Anticancer Effects: Review. Int J Mol Sci 14: 2410-2430.
27. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S (2013) Antiangiogenic effects of melatonin in endothelial cell cultures. Microvasc Res 87: 25-33.
28. Blask DE, Wilson ST, Zalatan F (1997) Physiological melatonin inhibition of human breast cancer cell growth in vitro: evidence for a glutathione-mediated pathway. Cancer Res 57: 1909-1914. (Pubitemid 27209720)
29. Mediavilla MD, Cos S, Sánchez-Barceló EJ (1999) Melatonin increases p53 and p21WAFl expression in MCF-7 human breast cancer cells in vitro. Life Sci 65: 415-420. (Pubitemid 29325284)
30. Sánchez-Barceló EJ, Cos S, Mediavilla D, Martínez-Campa C, González A, et al. (2005) Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222. (Pubitemid 41475432)
31. Fic M, Podhorska-Okolow M, Dziegiel P, Gebarowska E, Wysocka T, et al. (2007) Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo 3: 513-518. (Pubitemid 46901411)
32. Mirunalini S, Karthishwaran K, Dhamodharan G, Shalini M (2010) Studies on the chemopreventive potential of melatonin on 7,12- dimethylbenz(a)anthracene induced mammary carcinogenesis in rats. J Appl Sci Res 6: 245-253.
33. Cui P, Luo Z, Zhang H, Su Y, Li A, et al. (2006) Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 41: 358-362. (Pubitemid 44498222)
34. Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, et al. (2001) Antiangiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett 22: 45-47. (Pubitemid 32186250)
35. Kaur C, Sivakumar V, Lu J, Ling EA (2007) Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland. J Pineal Res 42: 338-349. (Pubitemid 46581657)
36. Dai M, Cui P, Yu M, Han J, Li H, et al. (2008) Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res 22: 121-126. (Pubitemid 351252913)
37. Park JW, Hwang MS, Suh SI, Baek WK (2009) Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells. J Pineal Res 4: 415-421.
38. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980) Light suppresses melatonin secretion in humans. Science 210: 1267-1269. (Pubitemid 11178017)
39. Cos S, Sánchez-Barceló EJ (2000) Melatonin and mammary pathological growth. Front Neuroendocrinol 21: 133-170. (Pubitemid 30228502)
40. Jensen MM, Jorgensen JT, Binderup T, Kjaer A (2008) Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 8: 16.
41. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, et al. (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 31: 2022-2028.
42. Blankenberg FG, Backer MV, Levashova Z, Patel V, Backer JM (2006) In vivo tumor angiogenesis imaging with site-specfic labeled (99m)Tc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33: 841-848. (Pubitemid 43979693)
43. Ali MM, Janic B, Babajani-Feremi A, Varma NR, Iskander AS, et al. (2010) Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PloS One 5: e8727.
44. Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
45. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, et al. (2009) Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8: 337-346.
46. Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE (1992) The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 64: 249-256.
47. Leman ES, Sisken BF, Zimmer S, Anderson KW (2001) Studies of the Interactions Between Melatonin and 2 Hz, 0.3 mT PEMF on the proliferation and Invasion of Human Breast Cancer Cells. Bioelectromagnetics 22: 178-184. (Pubitemid 33608392)
48. Jung JH, Sohn EJ, Shin EA, Lee D, Kim B, et al. (2013) Melatonin Suppresses the Expression of 45S Preribosomal RNA and Upstream Binding Factor and Enhances the Antitumor Activity of Puromycin in MDA-MB-231 Breast Cancer Cells. Evid Based Complement Alternat Med doi: 10.1155/2013/879746.
49. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM (2002) MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol 192: 147-156. (Pubitemid 34667233)
50. Jablonska K, Pula B, Zemla A, Owczarek T, Wojnar A, et al. (2013) Expression of melatonin receptor MT1 in cells of human invasive ductal breast carcinoma. J Pineal Res 54: 334-345.
51. Hill SM, Blask DE, Xiang S, Yuan L, Mao L, et al. (2011) Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 16: 235-245.
52. Oprea-Ilies G, Haus E, Sackett-Lundeen L, Liu Y, McLendon L, et al. (2013) Expression of melatonin receptors in triple negative breast cancer (TNBC) in African American and Caucasian women: relation to survival. Breast Cancer Res Treat 137: 677-687.
53. Cos S, Fernández R, Güézmes A, Sánchez- Barceló EJ (1998) Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390. (Pubitemid 28450041)
54. Rao GN, Ney E, Herbert RA (2000) Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treat 64: 287-296. (Pubitemid 32055837)
55. Liu H, Xu L, Wei JE, Xie MR, Wang SE, et al. (2011) Role of CD4 + CD25 + regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro. Anat Rec (Hoboken) 294: 781-788.
56. Cui P, Yu M, Peng X, Dong L, Yang Z (2012) Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human umbilical vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. J Pineal Res 52: 236-243.
57. Proietti S, Cucina A, Reiter RJ, Bizzarri M (2013) Molecular mechanisms of melatonin's inhibitory actions on breast cancers. Cell Mol Life Sci 70: 2139-2157.
58. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, et al. (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with singlechain VEGF-based probes. Nat Med 13: 504-509. (Pubitemid 46559824)
59. Plate KH, Breier G, Millauer B, Ullrich A, Risau W (1993) Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827. (Pubitemid 23360294)
60. Johansson I, Aaltonen KE, Ebbesson A, Grabau D, Wigerup C, et al. (2012) Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis. Genes Chromosomes Cancer 51: 375-383.
61. Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, et al. (2013) Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal Res 54: 264-270.
62. Holmes K, Roberts OL, Thomas AM, Cross MJ (2007) Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012. (Pubitemid 47354167)
63. Cui P, Yu M, Luo Z, Dai M, Han J, et al. (2008) Intracellular signaling pathways involved in cell growth inhibition of human umbilical vein endothelial cells by melatonin. J Pineal Res 44: 107-114. (Pubitemid 350231103)
64. Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S (2012) Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res doi: 10.1111/jpi.12007.
65. Margheri M, Pacini N, Tani A, Nosi D, Sguecco R, et al. (2012) Combined effects of melatonin and all-trans retinoic acid and somatostatin on breast cancer cell proliferation and death: molecular basis for the anticancer effect of these molecules. Eur J Pharmacol 681: 34-43.
66. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzaniga M, et al. (1995) Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71: 854-856